News and Trends 2 Nov 2022 AELIX Therapeutics publishes positive data on its HIV vaccine Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 United BioPharma gets FDA approval for phase 2 HIV drug trial Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […] August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 First patient receives new immunotherapy drug for HIV in clinical trial A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2021 As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances. HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence […] September 8, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2021 HIV Drug Approvals Lift Hopes Amid Missed UN Targets The recent approvals of long-acting HIV injections promise to lighten the load of HIV sufferers around the world. However, a vital UN deadline for improving global HIV healthcare has slipped away. At the end of January, ViiV Healthcare’s Cabenuva became the first long-acting HIV treatment to be approved by the FDA. This decision, in addition […] February 4, 2021 - 6 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2020 ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […] March 23, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Update: Cancer Immunotherapy Biotech Files for Insolvency Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […] December 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2019 ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […] November 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2019 Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […] August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2019 HIV Drug Suppresses Virus for Almost Two Years When Other Treatments Fail A first-in-class HIV treatment developed by the UK company ViiV Healthcare has suppressed the virus in people who have become resistant to other antiretroviral drugs, providing protection for at least 96 weeks. The phase III trial tested ViiV Healthcare’s first-in-class drug fostemsavir in 272 HIV-infected people who had failed to respond to approved antiretroviral drugs. […] July 23, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2019 EU Approves Two-Drug Pill as First-Line Treatment for HIV The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […] July 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Jun 2019 This Biotech Reduces Drug Side Effects Using Silica Gel Implants DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over time, causing fewer side effects and helping patients stick to their treatment regimen. Mission: To develop silica gels that slowly release drugs over time to treat conditions including HIV, hepatitis B, retinal disease and cancer. One big problem in chronic […] June 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email